Asset Details
Do you wish to reserve the book?
Delayed Onset of Malaria — Implications for Chemoprophylaxis in Travelers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Delayed Onset of Malaria — Implications for Chemoprophylaxis in Travelers
Do you wish to request the book?
Delayed Onset of Malaria — Implications for Chemoprophylaxis in Travelers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Delayed Onset of Malaria — Implications for Chemoprophylaxis in Travelers
2003
Overview
This study identified 300 patients in Israel and 2822 in the United States who presented with clinical malaria after travel to areas of endemic disease. Of these patients, 36 percent presented more than two months after returning home, and most had used an antimalarial regimen according to national guidelines.
A different strategy is needed.
The appropriate choice of drugs for chemoprophylaxis against malaria in travelers remains controversial and is affected by several issues, including drug efficacy, tolerance, convenience, and cost. The declining efficacy of chloroquine against
Plasmodium falciparum
in most malarious areas of the world precludes the routine use of this drug, which was the mainstay of prophylaxis and treatment for decades. Given the low risk of infection for many travelers, drug tolerance may limit use if adverse effects are too frequent or severe. For example, amodiaquine and sulfadoxine–pyrimethamine were found to have low but unacceptable rates of severe adverse effects.
1
–
3
Concern about . . .
Publisher
Massachusetts Medical Society
Subject
Antimalarials - therapeutic use
/ Biological and medical sciences
/ Chloroquine - therapeutic use
/ Endemic Diseases - prevention & control
/ Humans
/ Malaria
/ Malaria - prevention & control
/ Malaria, Falciparum - epidemiology
/ Malaria, Falciparum - prevention & control
/ Malaria, Vivax - epidemiology
/ Malaria, Vivax - prevention & control
/ Mefloquine - therapeutic use
/ Proteins
/ Travel
